Can you discuss the economic implications of dexmedetomidine use and any strategies for optimizing its cost-effectiveness in healthcare settings?

Indunil Karunarathna @Indunil-Karunarathna

09 May 2024 1 7K Report

Can you discuss the economic implications of dexmedetomidine use and any strategies for optimizing its cost-effectiveness in healthcare settings?Article Dexmedetomidine: A Comprehensive Review of Pharmacology, Cli...

Indunil Karunarathna

Article Dexmedetomidine: A Comprehensive Review of Pharmacology, Cli...

The economic implications of dexmedetomidine use in healthcare settings can be significant, given its higher acquisition cost compared to some traditional sedatives and analgesics. However, several factors contribute to its potential cost-effectiveness, and there are strategies for optimizing its economic impact:

Reduced Length of Stay: Dexmedetomidine's sedative properties, combined with its minimal respiratory depression and favorable side effect profile, may lead to shorter lengths of stay in intensive care units (ICUs) and reduced duration of mechanical ventilation. This can result in cost savings by freeing up ICU beds and reducing healthcare resource utilization.

Lower Incidence of Adverse Events: Dexmedetomidine has been associated with lower rates of delirium, respiratory depression, and hemodynamic instability compared to some traditional sedatives and opioids. By minimizing the occurrence of adverse events, dexmedetomidine may reduce the need for additional interventions, treatments, or prolonged hospitalizations, resulting in potential cost savings.

Improved Patient Outcomes: Dexmedetomidine's ability to provide effective sedation and analgesia while preserving natural sleep architecture and minimizing delirium may contribute to improved patient outcomes, including reduced morbidity and mortality. While difficult to quantify in economic terms, these improvements in patient outcomes can have long-term cost implications by reducing the need for additional healthcare services and treatments.

Optimizing Dosage and Infusion Strategies: Healthcare providers can optimize the cost-effectiveness of dexmedetomidine use by carefully selecting appropriate dosing regimens and infusion strategies based on patient-specific factors, clinical indications, and institutional protocols. Tailoring dexmedetomidine therapy to individual patient needs can help minimize unnecessary resource utilization and maximize therapeutic benefits.

Formulary Management and Negotiation: Healthcare institutions can negotiate pricing agreements with manufacturers or wholesalers to secure favorable pricing for dexmedetomidine. Additionally, formulary management practices, such as therapeutic interchange programs or utilization review committees, can help ensure cost-effective use of dexmedetomidine and other sedatives within healthcare organizations.

Clinical Pathways and Protocols: Implementing standardized clinical pathways and protocols for dexmedetomidine use can help optimize its cost-effectiveness by promoting consistent and evidence-based practices across healthcare settings. These pathways may include criteria for patient selection, dosing guidelines, monitoring parameters, and criteria for discontinuation or dose adjustment.

Cost-Benefit Analysis: Conducting cost-benefit analyses or economic evaluations comparing dexmedetomidine to alternative sedatives and analgesics can provide valuable insights into its economic impact within specific healthcare settings. These analyses can consider both direct costs (e.g., drug acquisition costs, healthcare resource utilization) and indirect costs (e.g., patient outcomes, length of stay) to inform decision-making regarding dexmedetomidine use.

By considering these factors and implementing strategies to optimize its cost-effectiveness, healthcare institutions can maximize the value of dexmedetomidine use while ensuring high-quality patient care.

Badges
Science topic

More Indunil Karunarathna's questions See All

Detection and Identification of Amanitins in the Wood-Rotting Fungi Galerina fasciculata andGalerina helvoliceps

Dear all, Can anyone help me to contact the corresponding author of the paper " Muraoka, S., Fukamachi, N., Mizumoto, K., & Shinozawa, T. (1999). Detection and Identification of Amanitins in...

01 January 1970 6,517 3 View

Edible mushrooms and their cultivation

Hi All, Does anyone have the PDF of following book? Chang, S. T.; Miles, P. G. (1989). Edible mushrooms and their cultivation. Edible Mushrooms and Their Cultivation, 345. Thanks

01 January 1970 7,851 1 View

Is there a powerful system for the security of the systems distributed on IoT systems?

02 March 2021 3,858 10 View

How Relativistic effects is one reason for lanthanide contraction?

The Lanthanide contraction which is the decrease in ionic radii of the elements in the lanthanide series from atomic number 57, lanthanum, to 71, lutetium, is due to poor shielding of the 4f...

01 March 2021 2,272 4 View

Does the circuit modeling for planar monopole antennas using Foster canonical forms give good approximation?

Hi researchers, I am searching for some accurate way to do the circuit modeling of planar CPW-fed monopole antennas. I have gone through the literature where mostly circuit modeling is done using...

28 February 2021 7,016 1 View

For modelling epoxy-based matrices (in composites), which model in ABAQUS is the most suitable, Concrete damaged plasticity or Drucker-Prager model?

I am working on developing a micromechanical FE model for predicting kink-band formation in UD composites. To model matrix plasticity, which model, out of Concrete Damaged Plasticity and...

28 February 2021 5,415 1 View

Does RNAiMAX transfection reagent work in serum free medium?

I diluted siRNA and RNAiMAX in opti-MEM and added to the cells which they were in the growth medium. Is it a right way? or should I culture cells in the opti-MEM medium for a while and not in...

26 February 2021 10,041 3 View

Can anyone share his experience regards Smoothing in origin?

I am working on TiO2 composite material and the results of XRD have a lot of small/junk peaks and while I apply a smooth filter in Origin then the other characteristics peaks disappear so anyone...

26 February 2021 8,183 3 View

How to calculate battery consumption for IoT device?

Hi, everyone I'm working on a privacy-preserving algorithm that will apply to IoT devices. So, I need to measure the power consumption by implementing this algorithm. Any suggestion, advice,...

25 February 2021 8,749 6 View

How vulnerable is water and wastewater infrastructure to cyber terrorism in an age of IoT?

Im looking for any papers, reports,articles, links etc on information on How vulnerable is water and wastewater infrastructure to cyber terrorism in an age of IoT.

24 February 2021 2,750 4 View

How to empty large intestine in mice ?

Hi all I am working on colon-targeted drug delivery for which I kept mice fasting for 6h using fasting grills during scotophase (dark period). I observed liquid fecal content in the cecum and...

23 February 2021 7,701 2 View

Why cannot world and community leaders be gentle? Where did ethics of care go?

The whole world is in a mess and paused. We all are tired of seeing hypermasculinized and destructive leaderships all around us. This world has seen enough of the aggressive patriarchal social...

23 February 2021 292 7 View